---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-25-000053"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T16:09:38.427040+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GRI Bio reports FY2024 net loss of $8.2M; cash runway into Q2 2025

## Summary
- Net loss of $8.2M for FY2024; R&D spend increased 19% to $3.8M; G&A fell 45% to $4.5M.
- Cash and equivalents of $5.0M at Dec 31, 2024; runway only into Q2 2025 (through interim data).
- Phase 2a interim data for GRI-0621 in IPF expected Q2 2025; topline results Q3 2025.
- European patent granted for GRI-0803 and library of 500+ proprietary NKT cell modulators.

## SEC filing metadata
- accession: 0001824293-25-000053
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429325000053/0001824293-25-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429325000053/val-20250317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-25-000053
- JSON: https://secwatch.observer/filing/0001824293-25-000053.json
- Plain text: https://secwatch.observer/filing/0001824293-25-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.